Rezolute Inc (RZLT)
3.90
-0.34
(-8.02%)
USD |
NASDAQ |
Jun 25, 16:00
3.90
0.00 (0.00%)
After-Hours: 20:00
Rezolute Research and Development Expense (Annual): 43.81M for June 30, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| June 30, 2023 | 43.81M |
| June 30, 2022 | 32.49M |
| June 30, 2021 | 14.99M |
| June 30, 2020 | 14.45M |
| June 30, 2019 | 19.08M |
| June 30, 2018 | 17.28M |
| Date | Value |
|---|---|
| June 30, 2017 | 12.09M |
| June 30, 2016 | 9.448M |
| June 30, 2015 | 4.701M |
| June 30, 2014 | 0.0343M |
| June 30, 2013 | 0.0035M |
| June 30, 2012 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
14.45M
Minimum
2020
43.81M
Maximum
2023
24.96M
Average
19.08M
Median
2019
Research and Development Expense (Annual) Benchmarks
| Cytokinetics Inc | -- |
| Oragenics Inc | 15.49M |
| GT Biopharma Inc | 6.466M |
| IGM Biosciences Inc | 215.52M |
| 180 Life Sciences Corp | 2.784M |